- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06945718
Resultados clínicos del trazador verde de indocianina utilizando en gastrectomía laparoscópica con linfadenectomía extendida más allá de D2 para cáncer gástrico localmente avanzado (Fuges-30)
Ensayos controlados aleatorios prospectivos sobre resultados clínicos del trazador verde de indocianina utilizando en gastrectomía laparoscópica con disección de ganglios linfáticos extra regionales D2 para cáncer gástrico localmente avanzado (Fugues-30)
Taking patients with locally advanced gastric adenocarcinoma (cT2-4a, N-/+, M0) as the research subjects, to evaluate whether the clinical efficacy of laparoscopic beyond D2 regional lymph node dissection for gastric cancer with indocyanine green tracer is better or not.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Mi Lin, phD
- Número de teléfono: 13459152658
- Correo electrónico: silihuala@qq.com
Copia de seguridad de contactos de estudio
- Nombre: Hua-Long Zheng, phD
- Número de teléfono: 18359190587
- Correo electrónico: 291167038@qq.com
Ubicaciones de estudio
-
-
Fujian
-
Fuzhou, Fujian, Porcelana, 350001
- Reclutamiento
- Fujian Medical University Union Hospital
-
Contacto:
- Changming Huang, M.D., Ph.D.
- Número de teléfono: +86-133-6591-0253
- Correo electrónico: hcmlr2002@163.com
-
Investigador principal:
- Changming Huang, M.D., Ph.D.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
Descripción
Inclusion Criteria:
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) class I to III Written informed consent
Exclusion Criteria:
Women during pregnancy or breast-feeding Severe mental disorder History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) History of previous gastric surgery (including ESD/EMR for gastric cancer) Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging including enlarged or bulky lymph nodes in D3 region.
Other malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)<50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
laparoscopic gastrectomy with beyond D2 regional fluorescent lymph node dissection with ICG group
ICG with D2+ group |
dissect the lymph nodes outside the extent of D2 LN region. |
|
laparoscopic gastrectomy with D2 regional lymph node dissection with ICG group
ICG with D2 group |
dissect the lymph nodes outside the extent of D2 LN region. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
3-year disease free survival rate
Periodo de tiempo: 3 years
|
Disease-free survival is calculated from the day of surgery to the day of recurrence or death |
3 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total number of retrieved lymph nodes
Periodo de tiempo: 30 days
|
Total number of retrieved lymph nodes |
30 days
|
|
Noncompliance rate of lymph node dissection
Periodo de tiempo: 30 days
|
The LN dissection rate was determined by the number of patients in whom a LN station was harvested divided by the total number of patients who required retrieval at the corresponding LN station. Within the scope of D2 dissection, LN noncompliance was defined as the absence of LNs that should have been resected from > 1 LN station. |
30 days
|
|
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A
Periodo de tiempo: 30 days
|
Relationship between the number of fluorescent lymph nodes in group A and total number of lymph nodes in group A |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)
Periodo de tiempo: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Periodo de tiempo: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)
Periodo de tiempo: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group A (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)
Periodo de tiempo: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group A (false negative rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B
Periodo de tiempo: 30 days
|
Relationship between the number of fluorescent lymph nodes in group B and total number of lymph nodes in group B |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)
Periodo de tiempo: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group B (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)
Periodo de tiempo: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)
Periodo de tiempo: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group B (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)
Periodo de tiempo: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group B (false negative rate). |
30 days
|
|
Number of metastatic lymph nodes
Periodo de tiempo: 30 days
|
Number of metastatic lymph nodes |
30 days
|
|
Metastasis rate of lymph nodes
Periodo de tiempo: 30 days
|
Metastasis rate of lymph nodes |
30 days
|
|
Postoperative complications
Periodo de tiempo: 30 days
|
Postoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification. |
30 days
|
|
Mortality rates
Periodo de tiempo: 30 days
|
Patient died during hospitalization. |
30 days
|
|
3-year overall survival rate
Periodo de tiempo: 3 years
|
3-year overall survival rate |
3 years
|
|
3-year recurrence pattern
Periodo de tiempo: 3 years
|
3-year recurrence pattern |
3 years
|
|
Postoperative recovery course
Periodo de tiempo: 30 days
|
Time to first flatus after surgery, time to first ambulation after surgery, time to first liquid diet after surgery, time to first semi-liquid diet after surgery, length of hospital stay after surgery. |
30 days
|
|
The incidence of intraoperative complications
Periodo de tiempo: 30 days
|
Intraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications |
30 days
|
|
Inflammatory and immune response
Periodo de tiempo: 7 days
|
the values of hemoglobin, prealbumin, albumin, C-reactive protein, and white blood cell count from peripheral blood before the operation and on postoperative day 1, 3, 5 are recorded. |
7 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Chang-Ming Huang, Prof., Fujian Medical University Union Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FUGES-30
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .